CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 118 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,108,731 | +10.0% | 409,707 | -19.2% | 0.00% | 0.0% |
| Q2 2023 | $5,551,234 | +65.3% | 506,962 | +31.6% | 0.00% | 0.0% |
| Q1 2023 | $3,357,950 | -63.6% | 385,086 | -73.8% | 0.00% | -50.0% |
| Q4 2022 | $9,223,264 | +83.5% | 1,471,015 | +2.4% | 0.00% | +100.0% |
| Q3 2022 | $5,026,000 | +20.9% | 1,436,057 | +1.9% | 0.00% | 0.0% |
| Q2 2022 | $4,157,000 | +27.8% | 1,409,077 | +34.7% | 0.00% | 0.0% |
| Q1 2022 | $3,253,000 | -17.6% | 1,046,277 | -10.4% | 0.00% | – |
| Q4 2021 | $3,946,000 | +94.9% | 1,167,434 | +110.5% | 0.00% | – |
| Q3 2021 | $2,025,000 | -42.8% | 554,729 | -31.7% | 0.00% | – |
| Q2 2021 | $3,543,000 | -61.9% | 812,597 | -60.3% | 0.00% | -100.0% |
| Q1 2021 | $9,297,000 | -45.8% | 2,047,675 | -31.5% | 0.00% | -60.0% |
| Q4 2020 | $17,155,000 | +3.9% | 2,988,825 | +31.0% | 0.01% | 0.0% |
| Q3 2020 | $16,519,000 | +72.6% | 2,281,555 | -16.8% | 0.01% | +66.7% |
| Q2 2020 | $9,572,000 | +141.2% | 2,742,998 | +2.3% | 0.00% | +50.0% |
| Q1 2020 | $3,969,000 | -31.3% | 2,681,633 | -9.0% | 0.00% | 0.0% |
| Q4 2019 | $5,779,000 | -53.4% | 2,948,188 | +21.7% | 0.00% | -66.7% |
| Q3 2019 | $12,407,000 | -31.7% | 2,423,240 | -4.5% | 0.01% | -25.0% |
| Q2 2019 | $18,161,000 | -51.3% | 2,536,434 | -9.6% | 0.01% | -57.9% |
| Q1 2019 | $37,256,000 | +232.0% | 2,805,472 | +96.8% | 0.02% | +216.7% |
| Q4 2018 | $11,221,000 | +5.8% | 1,425,822 | +49.0% | 0.01% | +20.0% |
| Q3 2018 | $10,606,000 | -58.7% | 957,248 | -50.0% | 0.01% | -61.5% |
| Q2 2018 | $25,696,000 | +85.1% | 1,914,807 | +79.2% | 0.01% | +62.5% |
| Q1 2018 | $13,879,000 | +117.3% | 1,068,400 | +53.9% | 0.01% | +100.0% |
| Q4 2017 | $6,387,000 | +23.8% | 694,252 | +8.5% | 0.00% | 0.0% |
| Q3 2017 | $5,159,000 | +7166.2% | 640,027 | +3801.7% | 0.00% | – |
| Q1 2017 | $71,000 | +184.0% | 16,404 | +29.2% | 0.00% | – |
| Q3 2016 | $25,000 | -46.8% | 12,692 | -53.1% | 0.00% | – |
| Q2 2016 | $47,000 | +213.3% | 27,050 | +146.4% | 0.00% | – |
| Q1 2016 | $15,000 | -91.8% | 10,979 | -58.4% | 0.00% | – |
| Q1 2015 | $183,000 | – | 26,373 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |